Advanced statistics identification of participant and treatment predictors associated with severe adverse effects induced by fluoropyrimidine-based chemotherapy

被引：0
|
作者：
Samantha K. Korver
Joanne M. Bowen
Rachel J. Gibson
Imogen A. Ball
Kate R. Secombe
Taylor J. Wain
Richard M. Logan
Jonathan Tuke
Kelly R. Mead
Alison M. Richards
Christos S. Karapetis
Dorothy M. Keefe
Janet K. Coller
机构：
[1] The University of Adelaide,Discipline of Pharmacology, School of Biomedicine
[2] The University of Adelaide,Discipline of Physiology, School of Biomedicine
[3] The University of Adelaide,School of Allied Health Science and Practice
[4] The University of Adelaide,Adelaide Dental School
[5] The University of Adelaide,School of Mathematical Sciences
[6] Flinders Medical Centre,Discipline of Medicine
[7] Flinders University,undefined
[8] The University of Adelaide,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2023年 / 91卷
关键词：
Fluoropyrimidine-based chemotherapy; Adverse effects; Risk; Logistic modeling; Bayesian network analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：507 / 521
页数：14
相关论文
共 14 条
  • [1] Advanced statistics identification of participant and treatment predictors associated with severe adverse effects induced by fluoropyrimidine-based chemotherapy
    Korver, Samantha K.
    Bowen, Joanne M.
    Gibson, Rachel J.
    Ball, Imogen A.
    Secombe, Kate R.
    Wain, Taylor J.
    Logan, Richard M.
    Tuke, Jonathan
    Mead, Kelly R.
    Richards, Alison M.
    Karapetis, Christos S.
    Keefe, Dorothy M.
    Coller, Janet K.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2023, 91 (06) : 507 - 521
  • [2] Capecitabine "metronomic" chemotherapy for palliative treatment of elderly patients with advanced gastric cancer after fluoropyrimidine-based chemotherapy
    He, ShengLi
    Shen, Jie
    Hong, Liang
    Niu, LuMing
    Niu, DaoYong
    MEDICAL ONCOLOGY, 2012, 29 (01) : 100 - 106
  • [3] Capecitabine “metronomic” chemotherapy for palliative treatment of elderly patients with advanced gastric cancer after fluoropyrimidine-based chemotherapy
    ShengLi He
    Jie Shen
    Liang Hong
    LuMing Niu
    DaoYong Niu
    Medical Oncology, 2012, 29 : 100 - 106
  • [4] Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Gastric Cancer: a Bayesian Network Meta-Analysis
    Zhu, Lucheng
    Liu, Jihong
    MA, Shenglin
    PATHOLOGY & ONCOLOGY RESEARCH, 2016, 22 (04) : 853 - 861
  • [5] Upfront DPYD Genotype-Guided Treatment for Fluoropyrimidine-Based Chemotherapy in Advanced and Metastatic Colorectal Cancer: A Cost-Effectiveness Analysis
    Fariman, Soroush Ahmadi
    Rafsanjani, Zahra Jahangard
    Hasanzad, Mandana
    Niksalehi, Kimia
    Nikfar, Shekoufeh
    VALUE IN HEALTH REGIONAL ISSUES, 2023, 37 : 71 - 80
  • [6] Cost-effectiveness of pembrolizumab plus platinum and fluoropyrimidine-based chemotherapy as first-line treatment of advanced esophageal cancer in the United States
    Qu, T.
    Zhong, Y.
    Zhang, S.
    Meng, Y.
    Joo, S.
    Shah, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S1059 - S1060
  • [7] Fluoropyrimidine-based doublet chemotherapy as second-line treatment for advanced biliary tract cancer: a meta-analysis of ABC-06 and NIFTY
    Rizzo, Alessandro
    Cusmai, Antonio
    Giovannelli, Francesco
    Acquafredda, Silvana
    Rinaldi, Lucia
    Misino, Andrea
    Palmiotti, Gennaro
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2022, 16 (03) : 273 - 278
  • [8] Incidence of hand–foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen
    Carlos Gómez-Martin
    Antonio Sánchez
    Antonio Irigoyen
    Beatriz Llorente
    Begoña Pérez
    Raquel Serrano
    Mª José Safont
    Esther Falcó
    Adelaida Lacasta
    Margarita Reboredo
    Jorge Aparicio
    Rosario Dueñas
    Marta Llanos Muñoz
    Pilar Regueiro
    Elena Sanchez-Viñes
    Rafael López López
    Clinical and Translational Oncology, 2012, 14 : 689 - 697
  • [9] Cost Effectiveness of Adding Pembrolizumab to Platinum and Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A US Healthcare Payer’s Perspective
    Tingting Qu
    Shujing Zhang
    Yichen Zhong
    Yang Meng
    He Guo
    Seongjung Joo
    Peter C. Enzinger
    PharmacoEconomics, 2022, 40 : 1247 - 1259
  • [10] Cost Effectiveness of Adding Pembrolizumab to Platinum and Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A US Healthcare Payer's Perspective
    Qu, Tingting
    Zhang, Shujing
    Zhong, Yichen
    Meng, Yang
    Guo, He
    Joo, Seongjung
    Enzinger, Peter C.
    PHARMACOECONOMICS, 2022, 40 (12) : 1247 - 1259
12